Insider · CIK 0001946366
Kamal Hamed
Files at SPRO (Spero Therapeutics, Inc.). First filing Feb 5, 2024, latest Feb 5, 2024.
In brief
Kamal Hamed files SEC Form 4 as officer at SPRO (Spero Therapeutics, Inc.). Since Feb 5, 2024, Kamal Hamed has reported 0 open-market buys worth $0 and 1 open-market sell worth $38k, the latest filed on Feb 5, 2024.
A track record needs three past buys with six months of prices behind them; Kamal Hamed has 0, so none is measured yet.
The newest scored trade: sold $38k of SPRO on Feb 2, 2024, filed Feb 5, 2024, scored 36 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SPRO: Spero Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Spero Therapeutics, Inc. | $38k 28,075 shares | -3% | +46% from low-25% from high |
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | SPRO Spero Therapeutics, Inc. | AGrant or award Common Stock | +239,731 | $0.00 | $0 | 816,192 | Feb 5, 2024 |
| Feb 2, 2024 | SPRO Spero Therapeutics, Inc. | SOpen-market sale Common Stock | -28,075 | $1.37 | $38k | 788,117 | Feb 5, 2024 |
Questions about Kamal Hamed
Answered from the filings on this page, as of the latest one.
Is Kamal Hamed buying or selling?
Not in the last 12 months. Kamal Hamed's latest open-market trade on SEC Form 4 was sold $38k of SPRO on Feb 2, 2024.
How did Kamal Hamed's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kamal Hamed has 0.
Where does Kamal Hamed file Form 4?
Kamal Hamed has filed Form 4 at SPRO (Spero Therapeutics, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.